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THE BRAZILIAN PORTUGUESE VALIDATION OF THE URINARY
INCONTINENCE-SPECIFIC QUALITY OF LIFE INSTRUMENT- I-QOL
Souza CC1, Fonseca ESM2, Fonseca MCM2, Sartori MGF2, Girão MJBC2, Castro RA2
1Federal University of São Paulo, São Paulo, Brazil, 2UNIFESP – Federal University of Sao
Paulo, Sao Paulo, Sao Paulo, Brazil
OBJECTIVES: The objective of this study was to cross-culturally adapt and validate 
the Incontinence-Speciﬁ c Quality of Life instrument (I-QOL) for Brazilian women with 
urinary incontinence. METHODS: The I-QOL is a scale devised to assess quality of 
life impairment due to urinary incontinence. This questionnaire has been used in 
numerous studies to evaluate the consequences of the disease in daily life or the effects
of different treatments. Seventy patients with urinary incontinence, were enrolled from
the outpatient clinic of the Uroginecology and Vaginal Surgery Section of the Gynecol-
ogy Department of the Federal University of São Paulo (UNIFESP). Initially, we 
translated the I-QOL into Brazilian Portuguese language following international meth-
odological recommendations. Due to language and cultural differences we performed
cultural, structural, conceptual, and semantic adaptation on the I-QOL, in order that
patients were able to fully understand the questions. All patients answered I-QOL 
twice on the same day with an interval of 30 minutes, applied by two different inter-
viewers. Also the Kingxs Health Questionnaire (KHQ), already translated and vali-
dated to Brazilian Portuguese was applied to the patients. After 7 to 15 days, by phone
interview, only I-QOL was applied again. Reliability (intra and inter observer internal
consistency), construct and discriminative validity were tested. RESULTS: Several
cultural adaptations were necessary until we reached the ﬁ nal version. The intra-
observer internal consistence (alpha of Cronbachxs) of the several dimensions varied
from moderate to high (0.77–0.93), and the inter observer internal consistence varied
from 0.65 to 0.88. Moderate to strong correlation was detected among the I-QOL
dominions and the validated Brazilian Portuguese version of KHQ. CONCLUSIONS:
I-QOL was adapted to the Portuguese language and to the Brazilian culture, showing
good reliability and validity. This questionnaire is now being evaluated in clinical trials
on new therapeutic strategies for urinary incontinence in Brazil.
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THE FDA DRAFT GUIDANCE ON PATIENT-REPORTED OUTCOMES CAN
BE USED TO IMPROVE THE ESTIMATION OF UTILITIES. A CASE STUDY
IN CHRONIC KIDNEY DISEASE
Lloyd A1, Falconer S1, Halton J2, Pandya B3, Pang F2
1Oxford Outcomes Ltd, Oxford, UK, 2Takeda Global Research and Development (Europe), 
London, UK, 3Takeda Pharmaceuticals North America, Inc, Deerﬁ eld, IL, USA
OBJECTIVES: The FDA draft guidance on patient-reported outcomes (PROs) outlines
methods for developing disease-speciﬁ c PROs. The aim of the present study was to
develop and validate vignette descriptions of health-related quality of life (HRQL) in 
people who have anemia associated with chronic kidney disease (CKD) by adapting 
the FDA methods for developing PROs to derive health state utilities. METHODS:
Interviews with people with CKD (n  12) provided detailed qualitative data regarding
patients’ HRQL. Qualitative analysis identiﬁ ed how HRQL varied by three levels of 
anemia (mild  12.5 g/dL; moderate 12.5–10.5 g/dL, and severe  10.5 g/dL; set
according to the recent National Institute of Clinical Excellence [NICE] clinical guide-
lines on CKD) and three states of CKD (pre-dialysis, peritoneal dialysis, and hemodi-
alysis). Vignette descriptions of HRQL were developed for each state, and patients 
and clinicians assessed content validity. Vignettes were rated by 100 members of the
general public in the UK using the time trade-off interview to estimate health state 
utilities. RESULTS: The qualitative data produced very detailed vignettes that were 
determined by patients and clinicians to have good content validity. Utilities varied 
for pre-dialysis (0.787–0.431), peritoneal dialysis (0.725–0.351), and hemodialysis
(0.629–0.331) between mild to severe levels of anemia, respectively. CONCLUSIONS:
The vignette descriptions were based upon qualitative data and validated through
content validation interviews with clinicians and patients. To our knowledge, this is
the ﬁ rst study in which vignettes have been developed entirely based on qualitative
data from patient interviews. This is a useful method for estimating utilities when no 
data from generic instruments are available.
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PATIENT PREFERENCE FOR TAMSULOSIN OCAS (ORAL CONTROLLED 
ABSORPTION SYSTEM) OVER TAMSULOSIN MODIFIED RELEASE 
CAPSULES
Khastgir J1, Odeyemi I2, Sidhu M2
1Morriston Hospital ABM University Hospitals Trust, Swansea, Wales, UK, 2Astellas Pharma 
Europe Ltd, Staines, Middlesex, UK
OBJECTIVES: Tamsulosin Ocas (oral controlled absorption system) is an improved
formulation of tamsulosin modiﬁ ed release (MR) capsules, providing a smoother 24h
plasma concentration proﬁ le, improved Cmax/C24h ratio, and independence from
oral food intake [1]. The formulations are similarly effective, but tamsulosin Ocas is 
associated with a lower incidence of orthostatic hypotension and abnormal ejaculation 
[2,3]. Our objective was to determine if patients preferred tamsulosin Ocas over tam-
sulosin MR. METHODS: Discrete Choice Analysis based on 12 hypothetical paired
scenarios was used to compare patient preferences in 50 men aged q45 years with
LUTS/BPH. Each scenario included convenience of administration with/without food, 
frequency of orthostatic hypotension, ejaculatory dysfunction, and out-of-pocket
expenses; one mandatory pair tested for irrationality. Disease severity and health-
related quality of life were assessed by IPSS and EuroQol EQ-5D. RESULTS: 56% of 
the trial population had moderate and 26% had severe symptoms on IPSS scores;
mean EQ-5D was 0.78. Five respondents with irrational responses were excluded.
Respondents were signiﬁ cantly more likely to prefer tamsulosin Ocas over MR overall 
(OR 19.45; 95% CI 6.27, 60.39; p  0.001). Orthostatic hypotension was the most
important factor driving this preference (OR 9.07; 95% CI 4.61, 17.82; p  0.001). 
On average, participants would have been willing to pay an extra 72.00GBP per 
month (range 32.40–144.40) for tamsulosin Ocas over MR; orthostatic hypotension 
contributed 76% to the choice for overall WTP. CONCLUSIONS: There was a strong 
patient preference for tamsulosin Ocas over tamsulosin MR that was primarily driven
by the orthostatic hypotension attribute. This preference equated to patients being 
willing to pay about 72GBP more per month for tamsulosin OCAS; the actual cost 
differential between the two formulations is 11.27GBP. REFERENCES: [1] Chapple
CR, Chartier-Kastler E. BJU Int 2006;29Suppl.):S9–12.; [2] Chapple CR, et al. Eur 
Urol 2005;4(Suppl.):S33–44; [3] Michel MC, et al. Eur Urol 2005;4(Supp.):S53–60.
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IMPACT OF SOLIFENACIN ON SYMPTOM BOTHER, HEALTH-RELATED
QUALITY OF LIFE, WORK PRODUCTIVITY, TREATMENT SATISFACTION, 
AND SYMPTOMS IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS
FROM VIBRANT
Mitcheson HD1, Roy JB2, Gilmet G3, Marshall TS3, Shannon JB4
1Bay State Clinical Trials, Inc, Watertown, MA, USA, 2Edmond Medical Center, Edmond, OK, 
USA, 3Astellas Pharma US, Inc., Deerﬁ eld, IL, USA, 4GlaxoSmithKline, Research Triangle Park, 
NC, USA
OBJECTIVES: To assess the efﬁ cacy of solifenacin on patient-reported outcomes and
diary-documented Overactive Bladder (OAB) symptoms. METHODS: 768 patients 
with OAB for q3 months were randomized to ﬂ exibly dosed solifenacin (5–10 mg) or 
placebo for 12 weeks; dose modiﬁ cations were permitted at Weeks 4 and 8. At baseline 
and Week 12, patients completed the Overactive Bladder Questionnaire (OAB-q),
comprised of a Symptom Bother scale (primary endpoint) and Health-Related Quality 
of Life (HRQL) scale with 4 domains (Coping, Concern, Sleep, Social Interactions),
Work Productivity and Activity Impairment (WPAI) Questionnaire, which assesses the 
impact of bladder-related problems on absenteeism (work time missed), presenteeism
(impairment at work), work productivity loss, and activity impairment, a 100-mm
Treatment Satisfaction Visual Analog Scale (TS-VAS; higher values indicate greater 
satisfaction) and 3-day bladder diaries for recording episodes of urgency, incontinence,
micturition frequency, and nocturia. RESULTS: By study end, solifenacin versus 
placebo signiﬁ cantly improved mean OAB-q Symptom Bother (29.9 vs 20.4, P 
0.0001), HRQL total (25.3 vs 16.7, P  0.0001) and all domain scores (all Ps 
0.0001). WPAI results revealed that solifenacin versus placebo signiﬁ cantly improved 
presenteeism (14.6% vs 8.7%), work productivity loss (12.9% vs 8.2%), and 
activity impairment (18.1% vs 14.7%; all Ps  0.01), but not absenteeism (0.5 vs 
0.1; P  0.50), likely because baseline levels were low (1.1% vs. 1.4%). On the TS-
VAS, mean change from baseline was signiﬁ cantly larger among solifenacin versus
placebo patients (38.2 vs 18.4; P  0.0001). Solifenacin vs placebo also signiﬁ cantly 
reduced mean daily episodes of urgency (3.05 vs 1.84; P  0.0001), incontinence
(1.85 vs 1.24; P  0.003), and frequency (2.23 vs 1.36; P  0.0001), but not 
nocturia (0.63 vs 0.48; P  0.34). CONCLUSIONS: Flexibly dosed solifenacin sig-
niﬁ cantly improved OAB symptom bother, HRQL, work productivity, and OAB 
symptoms. Patients who received solifenacin versus placebo also showed a signiﬁ cantly 
greater increase in overall treatment satisfaction.
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PROFILING COMMON CO-MORBIDITIES AND MEDICATIONS
PRESCRIBED AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE
Rasu R1, Karve S2, Abercrombie M3, Balkrishnan R2
1University of Missouri- Kansas City, Kansas City, MO, USA, 2Ohio State University, Columbus, 
OH, USA, 3University of Missouri Kansas City, Kansas City, MO, USA
OBJECTIVES: Patients with chronic kidney disease (CKD) often have ﬁ ve to six other
co-morbid conditions thus requiring extensive therapeutic treatment. Therefore, the
objective of this study was to examine the most common co-morbid conditions and
medications prescribed among patients with CKD, using a recent national population 
based ambulatory care survey. METHODS: This study utilized the National Ambula-
tory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical 
Care Survey (NHAMCS) data from 2002 through 2005. The NAMCS and NHAMCS
are national probability surveys of visits to ofﬁ ce-based physicians and ambulatory
services in hospital outpatient and emergency departments. CKD-related visits were 
identiﬁ ed using diagnosis codes (ICD-9-CM: 016.0, 572.4, 580–588, 591, 593.9,
572.4, 753.1, 753.3, 753.2, V18.6,794.4) or prescription for CKD speciﬁ c medica-
tions (brand and generic drug codes: calcium acetate,sevelamer,lanthanum car-
bonate,cinacalcet). Frequency analysis of the CKD visits by setting and demographic
characteristics was performed. Similarly, frequency analysis was performed to identify
the most common co-morbid diagnosis and medications prescribed among CKD 
patients. National estimates on visits were estimated using patient visits weights pro-
vided in the NAMCS and NHAMCS. RESULTS: In, 2005 there were 9.7million visits
related to CKD, 8.1 million physician ofﬁ ce visits, 0.9 million emergency department,
and 0.7 million outpatient hospital department visits, representing a 140% increase 
compared to 7.1 million visits in 2002. The most common co-morbid conditions
among CKD patients were essential hypertension (22.3%), diabetes mellitus (17.5%),
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anemia (5.4%), coronary atherosclerosis (4.5%), and congestive heart failure (3.5%).
Similarly, the most commonly prescribed medications among CKD patients were 
furosemide (16.3), atorvastatin (9.1%), lisinopril (9.0%), amlodipine (9%), aspirin
(8.6%), levothyroxine (7.9%), metaraminol (7.8%), insulin (7.4), atenolol (6.1%),
and potassium replacement solutions (5.3%). CONCLUSIONS: Our study identiﬁ es
the most common co-morbidities diagnosed among CKD patients. Early screening and 
treatment for these conditions may help lower the rate of progression of CKD.
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IMPACTS OF THE PREVENTIVE TREATMENT OF PATIENTS SUFFERING
FROM RECURRING CYSTITIS BY MEANS OF A STANDARD DRY
CRANBERRY EXTRACT
Taieb C
Pierre Fabre, Boulogne, France
OBJECTIVES: Assess the impacts of the preventive treatment of patients suffering
from recurring cystitis by means of a standard dry cranberry extract. METHODS: An
observational, longitudinal and prospective assessment by Urologists as part of their 
professional everyday activity. RESULTS: Ninety-two female patients, with an average 
age of 53.9–18.9 years, were included in the study. These patients had been monitored
for a period of 7 months (median). Before inclusion, 89 of the patients (96.7%) had
been offered an antibiotherapy. Depending on the patients, the factors that triggered 
their cystitis most frequently were: sexual relations (58.0%), alcohol consumption 
(27.6%) and diarrhoea (19.3%). The frequency and urgency of urination, the burning
sensation upon urination, the inability to completely empty the bladder and sensation 
of heaviness in the pubic region were the ﬁ ve symptoms assessed every three weeks. 
On inclusion, the scores for each symptom were, respectively: 6.2; 6.5; 6.1; 3.1 and
4.6. The overall score was 28.9. After 3 months, the scores for each symptom were, 
respectively: 1.6; 1.9; 1.9; 0.4 and 0.7. The overall score was 7.1. The evolution of 
the overall score (p  0.001) was signiﬁ cant, as was that of each respective symptom.
The prevalence of cystitis at 3 months was 47.6% (versus 96.7%) on inclusion. 
CONCLUSIONS: The prevalence of urinary problems in subjects suffering from
recurring cystitis was halved after 3 months of treatment by means of a standard dry
cranberry extract (96.7% versus 47.6%).
HEALTH CARE DECISION-MAKER’S CASE STUDIES POSTER SESSION
PCASE1
CASE STUDY OF CREATING A FORMULARY MANAGEMENT PROCESS
AT A COMPREHENSIVE CANCER CENTER IN BANGALORE, INDIA
Hariharaputhran D1, Ajai Kumar B1, Lal LS2
1Bangalore Institute of Oncology, HCG Enterprises Ltd, Bangalore, Karnataka, India, 
2University of Texas MD Anderson Cancer Center, Houston, TX, USA
ORGANIZATION: Bangalore Institute of Oncology (BIO). PROBLEM OR ISSUE 
ADDRESSED: Pharmacy and Therapeutics committee’s responsibilities consist
of developing policies and frameworks to develop an effective formulary taking 
into account both efﬁ cacy and cost considerations. In the Indian pharmaceutical 
environment, multiple manufactures compete for market share, within a single institu-
tion itself, creating inefﬁ ciencies in inventory management and the overall pharma-
ceutical budget. GOALS: The purpose of this project was to create a formulary for 
the Bangalore Institute of Oncology (BIO), taking into account both cost and efﬁ cacy 
considerations, while still maintaining physician preferences and autonomy. A prelimi-
nary ABC analysis, also known as a Pareto analysis, was conducted to identify items 
which have a signiﬁ cant impact on the overall inventory costs and well as, identify
and rank areas for improvement and management interventions. OUTCOMES 
ITEMS USED IN THE DECISION: The institutional ABC analysis was conducted for
the period of October 2006 to September 2007. Pharmaceutical items were valued 
(item cost multiplied by quantity issued/consumed in period) with the results subse-
quently ranked. IMPLEMENTATION STRATEGY: The total pharmacy budget for 
the ﬁ scal year was 15.89 Crore Rupees (Rs) (3.96 million US dollars, based on 40:1
exchange rate) with a resulting margin of 3.51 Crore Rupees (Rs) ($877,500), which 
consisted of 1033 different products from 247 manufacturers. The ABC analysis
revealed that 48 medications made up 85% of the total budget, with bortezomib being
the highest oncology contributor and meropenem being the highest non-oncology 
contributor. Analysis of purchases within the 35 oncology products revealed that there
were 29 manufacturers with 95 different brands, and for the 13 non oncology prod-
ucts, there were 14 manufacturers with 20 different brands. Based on this analysis,
consolidation of drug products and drug manufacturers were considered as an inter-
vention for formulary management by the Pharmacy and Therapeutics Committee. 
Three different options were considered by the committee. Option 1 consolidates to
only a single brand based on the highest margin, which would improve the present 
margin by 46% from 3.51 Crore Rs ($877,500) to 5.15 Crore Rs ($1,287,500).
Option 2 consolidates to having two brands, one from the preferred vendor with the 
highest margin and the other from the innovator/premium vendor, which would
improve the margin by 36% to 4.76 Crore Rs ($1,119,000). Option 3 consolidates 
to three brands: the preferred vendor with the highest margin, the lowest cost brand 
from the patient’s perspective, and the innovator/premium vendor brand, which would 
improve the margin by 24% to 4.36 Crore Rs ($1,090,000). Option 3 was chosen as
the basis for creating the institutional formulary, due to physician ﬂ exibility, patient
affordability, and improvements to the margin. RESULTS: The pharmaceutical 
company Dr. Reddy was selected as the preferred vendor for the creation of the for-
mulary and Option 3 was applied to all of the following pharmaceuticals(N): mono-
clonal antibodies(6); oral chemotherapy(23); intravenous chemotherapy(31); hormonal 
agents (9); and supportive care agents(13), for a total of 82 separate chemical entities.
Of the total 82 chemical entities, 43 (52.4%) have one brand available, 29 (35.4%) 
have two brands available, and 10 (12.2%) have three brands available. The preferred
vendor was utilized for 18 of these products. If the same total quantity is purchased 
again in 2008, the total purchase cost will be 54.15 Crore Rs ($13,538,047) with a 
resulting margin of 20.13 Crore Rs ($5,033,454). LESSONS LEARNED: Consolida-
tion of the pharmaceutical products and creation of a formulary results in higher than 
expected margin, even when the same purchase quantity is applied. Market competi-
tion forces appear to work better in an environment of a closed formulary system.
PCASE2
THE HOSPITAL AS IMPORTANT SOURCE OF INFORMATION
REGARDING CHARACTERISTICS OF HEALTH CARE USERS
Figueira CMG, Serrano E, Sena E
Vila Velha Hospital, Vila Velha, Espirito Santo, Brazil
ORGANIZATION Vila Velha Hospital (VVH). Vila Velha, Espirito Santo, Brazil. 
PROBLEM OR ISSUE ADDRESSED To assure client space and ﬁ delity in the market 
of health services through novel strategies able to supply health care providers 
with information about their clients and service costs at hospitals in the metropolitan
region of Vitoria-ES, Brazil. GOALS 1-Semestral increase of 30% in the number of 
clients referred for consultation at VVH and their ﬁ delity as a result of the good quality 
of services. 2-Semestral increase of 20% in VVH services required from health care
providers. OUTCOMES ITEMS USED IN THE DECISION Data from a search 
regarding the opinion of clients and health care providers about the ideal health ser-
vices were considered in the ﬁ nal decision. This information was obtained from 
PROAHSA (Program of Advanced Studies in Hospital Administration and Health
Systems) and from CHQ (Program of Quality Control of Medical Services). IMPLE-
MENTATION STRATEGY Analysis of patient stay at the hospital and its total cost,
considering age, site and disease of the client at VVH. All diseases described in ICD 
(International Classiﬁ cation of Diseases) were classiﬁ ed in acute, chronic and acciden-
tal, according to the duration of disease, loss of function, treatment type and length, 
and recurrence probability. RESULTS The data obtained allowed the comprehension
of characteristics of clients seen at VVH, and also allowed the proper estimation of 
treatment costs for various pathologies and the development of a cost curve per
pacient, materials and medications. LESSONS LEARNED The understanding of client 
speciﬁ cities allows price negotiation in a more secure and transparent way for both 
the hospital and the health care providers, and allows a more efﬁ cient handling of 
ﬁ nancial resources.
PCASE3
HTA PROCEDURES IN DRUG REIMBURSEMENT PROCESS IN POLAND. 
EVOLUTION OF RECOGNITION THE ROLE OF AGENCY OF HEALTH
TECHNOLOGY ASSESSMENT (AHTAPOL) BY POLICY MAKERS
Krol ZJ, Matusewicz W, Musialowicz A
Agency for Health Technology Assessment, Warsaw, Poland
ORGANIZATION: Agency of Health Technology Assessment Warsaw, Poland.
PROBLEM OR ISSUE ADDRESSED: Need to supply safe and most effective drugs, 
services and devices for publicly insured inhabitants through different mechanisms of 
spending public sources. GOALS: (1) Development a health technology assessment
procedures and incorporating its results into decision-making process of using public 
sources in Polish Health Care System. (2) Setting priorities of assessing areas – accord-
ing to health beneﬁ ts ﬁ nanced from public means reimbursement criteria. (3) Providing 
sufﬁ cient information for making decisions. OUTCOMES ITEMS USED IN THE
DECISION: There were different measurements performed during planning, imple-
menting and revising process of development AHTAPol. Measures were elaborated
parallel by national and international experts. IMPLEMENTATION STRATEGY:
AHTAPol was establish on 2006 as a governmental organization whose aims are:
assessment of medical procedures – health technologies; elaboration, veriﬁ cation, 
gathering and dissemination of information about HTA results of such assessments,
methodology and support of guidelines development made based on them; elaboration 
of recommendations for the Minister of Health concerning ﬁ nancing health technolo-
gies from public means (the role of the Consultative Council); collaboration with other 
authorities and organization acting in health care system and performing other duties
delegated by the Minister of Health (MoH) of Poland. One of the ﬁ rst actions of 
AHTAPol was related to delegation of MoH for development the basic beneﬁ t 
package. For the estimation of budget needed to services included into beneﬁ t package 
the costs calculating program was designed and pilot activities were performed. 
And ﬁ nally drug dossiers assessment and appraisal process led to recommendation 
for decision of MoH. These actions were supported by development department 
focused on analytical part and independent body – Consultative Council acting as an
appraisal committee RESULTS: Involvement of AHTAPol in activities related to based 
beneﬁ t package were limited to development of central medical services (with descrip-
tion of diagnoses and professional specialties) data-base. Costs calculation of these 
services was not started. Engagement of nationally recognized experts supported by
AHTAPol ended on development national cost calculating project. This project most 
probably will start in 2009. The most expected by policy-makers, public and clinicians 
activities of AHTAPol nowadays is involvement on the process of drug and modern 
medical technology reimbursement by elaboration of recommendations for decision 
of MoH. Organizational respond of AHTAPol resulted at the number of recommenda-
tion: 13 in 2007 and 81 in 2008. In 2009 is planed over 300. LESSONS LEARNED:
